XELLIA PHARMS APS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for XELLIA PHARMS APS, and what generic alternatives to XELLIA PHARMS APS drugs are available?
XELLIA PHARMS APS has fourteen approved drugs.
There are eight US patents protecting XELLIA PHARMS APS drugs.
There are fifty patent family members on XELLIA PHARMS APS drugs in thirty countries and twenty-six supplementary protection certificates in nine countries.
Summary for XELLIA PHARMS APS
| International Patents: | 50 |
| US Patents: | 8 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 14 |
Drugs and US Patents for XELLIA PHARMS APS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xellia Pharms Aps | MICAFUNGIN SODIUM | micafungin sodium | INJECTABLE;INTRAVENOUS | 211713-001 | Jun 2, 2021 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-001 | Feb 15, 2019 | RX | Yes | Yes | 10,849,956 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Xellia Pharms Aps | VANCOMYCIN HYDROCHLORIDE | vancomycin hydrochloride | SOLUTION;INTRAVENOUS | 211962-006 | May 13, 2020 | RX | Yes | Yes | 11,517,609 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XELLIA PHARMS APS Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Costa Rica | 20170234 | ⤷ Subscribe |
| Singapore | 11201703568W | ⤷ Subscribe |
| Croatia | P20200101 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for XELLIA PHARMS APS Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1115417 | CA 2006 00018 | Denmark | ⤷ Subscribe | PRODUCT NAME: DAPTOMYCIN |
| 1280520 | C01280520/01 | Switzerland | ⤷ Subscribe | PRODUCT NAME: TOBRAMYCIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 60565 01.02.2012 |
| 1280520 | 92678 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
